These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19373667)

  • 1. Biosimilars and safety issues.
    Dammacco F; Abbracchio MP; Gesualdo L; Goffredo F; Ronco C; Zanella A
    Leuk Lymphoma; 2009 Apr; 50(4):656-8. PubMed ID: 19373667
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilars: considerations for an abbreviated pathway.
    Kozlowski S; Behrman R
    Leuk Lymphoma; 2009 Apr; 50(4):527-8. PubMed ID: 19373649
    [No Abstract]   [Full Text] [Related]  

  • 3. Nature Biotechnology responds.
    Nat Biotechnol; 2014 Feb; 32(2):132. PubMed ID: 24509756
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 5. Lessons from Eprex for biogeneric firms.
    Louët S
    Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
    [No Abstract]   [Full Text] [Related]  

  • 6. The INN crowd.
    Nat Biotechnol; 2013 Dec; 31(12):1055. PubMed ID: 24316620
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharma's year of trouble and strife.
    Frantz S
    Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
    [No Abstract]   [Full Text] [Related]  

  • 8. A divided INN crowd.
    Schellekens H
    Nat Biotechnol; 2014 Feb; 32(2):132. PubMed ID: 24509755
    [No Abstract]   [Full Text] [Related]  

  • 9. A divided INN crowd.
    Eich G
    Nat Biotechnol; 2014 Feb; 32(2):131. PubMed ID: 24509754
    [No Abstract]   [Full Text] [Related]  

  • 10. A divided INN crowd.
    Greenwood J
    Nat Biotechnol; 2014 Feb; 32(2):131-2. PubMed ID: 24509753
    [No Abstract]   [Full Text] [Related]  

  • 11. A divided INN crowd.
    Chin WW
    Nat Biotechnol; 2014 Feb; 32(2):130. PubMed ID: 24509752
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of the pharmaceutical industry in drug development in dermatology.
    Cauwenbergh G
    Clin Dermatol; 2002; 20(5):467-73. PubMed ID: 12435516
    [No Abstract]   [Full Text] [Related]  

  • 13. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 14. Why EMA should provide clearer guidance on the authorization of NBCDs in generic and hybrid applications.
    Garattini L; Padula A
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):243-245. PubMed ID: 27997812
    [No Abstract]   [Full Text] [Related]  

  • 15. Current regulatory and scientific considerations for approving biosimilars in Iran.
    Hadavand N; Valadkhani M; Zarbakhsh A
    Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proposed European pharmacopeia monograph for continuous cell lines derived drugs.
    Dorpema JW
    Dev Biol Stand; 1989; 70():113-24. PubMed ID: 2759345
    [No Abstract]   [Full Text] [Related]  

  • 18. Equivocal role of micelles in Eprex adverse events.
    Smiell JM
    Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595347
    [No Abstract]   [Full Text] [Related]  

  • 19. Equivocal role of micelles in Eprex adverse events.
    Schellekens H; Crommelin DJ
    Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595346
    [No Abstract]   [Full Text] [Related]  

  • 20. The exploratory IND.
    Mills G
    J Nucl Med; 2008 Jun; 49(6):45N-47N. PubMed ID: 18511824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.